JAGSNPHARM Jagsonpal Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Jagsonpal Pharmaceuticals Limited reported a flattish Q3 FY26 performance with revenue at INR 73 crores, below expectations due to market headwinds and internal recalibration efforts. However, PAT grew 10% YoY to INR 12.5 crores, and the company generated INR 15.2 crores in free cash, bringing the balance to INR 176 crores. For the nine-month period, revenue grew 6% YoY to INR 223 crores, with PAT increasing 12.5% to INR 35.9 crores, and management anticipates double-digit growth from Q4 FY26 onwards.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 1.4%, net profit down 65.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 59 | 76 | 74 −1% | 73 −1% |
| EBITDA | 16 | 16 | 9 | 14 | 16 +0% | 16 +0% |
| Net profit | 11 | 32 | 7 | 11 | 13 +18% | 11 −66% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
